InfuSystem Holdings To Feature InfuBLOCK - its Highly Effective Alternative to Opioid Pain Management - at Outpatient Surgery Magazine's OR Excellence Conference
MADISON HEIGHTS, Mich., Oct. 2, 2018 /PRNewswire/ -- InfuSystem Holdings, Inc. (NYSE American: INFU) ("InfuSystem" or the "Company"), a leading national provider of infusion pumps and related services for the healthcare industry in the United States and Canada, today announced it will feature its InfuBLOCK Post-Op Pain Management program at Outpatient Surgery Magazine's OR Excellence Conference, taking place on October 3 – 5 at the Harbor Beach Marriott Resort and Spa in Fort Lauderdale, Florida.
Neill Saunders, InfuBLOCK's Division Director said, "InfuBLOCK for both the outpatient and inpatient settings, gives continuous peripheral nerve block programs a convenient and cost-saving way to do more blocks for more patients, reducing the reliance on opioid pain medication for post-surgical recovery. And the patients love it. Our satisfaction scores are consistently higher than 9 out of 10, which our customers love. InfuBLOCK offers superior accuracy in delivering the correct amount of medication in the infusion process compared to balloon-type infusion devices, helps manage our patient's pain better. Patients on the program are contacted daily by our InfuBLOCK team to monitor progress, pain levels, and satisfaction. InfuBLOCK's ultra-high patient satisfaction scores show InfuBLOCK's ability to effectively manage pain while avoiding the deleterious effects associated with taking opioid medications."
According to the National Institutes of Health, "Taking opioids over a long period of time produces dependence, such that when people stop taking the drug, they have physical and psychological symptoms of withdrawal. Dependence is not the same thing as addiction; although everyone who takes opioids for an extended period will become dependent.
"Misuse of prescription opioids and heroin affects more than 2 million Americans and an estimated 15 million people worldwide each year. The prevalence of opioid misuse and addiction is rapidly increasing. In 2016, more than 20,000 deaths in the United States were caused by an overdose of prescription opioids, and another 13,000 deaths resulted from heroin overdose. Drug overdoses are now the leading cause of death in U.S. adults under age 50, and opioids account for more than half of all drug overdose deaths."
Mr. Saunders continued, "InfuBLOCK is an effective and safe protocol for managing post-operative pain. Patients recover in the comfort of their own home with a non-opioid, consistent method for pain management along with our entire team to support them as they recover. Helping patients manage post-op pain as they heal, while minimizing their reliance on opioid pain medications, is our cause and is more important today than ever. While opioid medications have a place in the overall treatment of pain, InfuBLOCK can be a superior alternative to going home with opioid pain medications alone.
"Additionally, facilities that offer the InfuBLOCK program will experience significant cost savings compared to balloon-type elastomeric pumps currently in use. We look forward to showcasing InfuBLOCK at Outpatient Surgery Magazine's OR Excellence Conference on October 3 – 5, 2018 in Fort Lauderdale, Florida."
About InfuSystem Holdings, Inc.
InfuSystem Holdings, Inc. is a leading provider of infusion pumps and related services to hospitals, oncology practices and other alternate site healthcare providers. Headquartered in Madison Heights, Michigan, the Company delivers local, field-based customer support and also operates Centers of Excellence in Michigan, Kansas, California, Georgia and Ontario, Canada. The Company's stock is traded on the NYSE American under the symbol INFU.
Statements made in this press release that are not historical facts are considered to be forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended (the "Securities Act") and Section 21E of the Securities Exchange Act of 1934, as amended (the "Exchange Act"). The words "believe," "may," "will," "estimate," "continue," "anticipate," "intend," "should," "plan," "expect," "strategy," "future," "likely," variations of such words, and other similar expressions, as they relate to the Company, are intended to identify forward-looking statements. However, the absence of these words or similar expressions does not mean that a statement is not forward-looking. Forward-looking statements include statements relating to future actions, business plans, objectives and prospects, future operating or financial performance, including the preliminary financial results contained in this press release. In connection with the "safe harbor" provisions of the Private Securities Litigation Reform Act of 1995, the Company is identifying certain factors that could cause actual results to differ, perhaps materially, from those indicated by these forward-looking statements. Those factors, risks and uncertainties include, but are not limited to, the potential changes in overall healthcare reimbursement, including Centers for Medicaid and Medicare Services ("CMS") competitive bidding and fee schedule reductions, sequestration, concentration of customers, increased focus on early detection of cancer, competitive treatments, dependency on Medicare Supplier Number, availability of chemotherapy drugs, global financial conditions, changes and enforcement of state and federal laws, natural forces, competition, dependency on suppliers, risks in acquisitions & joint ventures, U.S. Healthcare Reform, relationships with healthcare professionals and organizations, technological changes related to infusion therapy, the Company's ability to implement information technology improvements and to respond to technological changes, dependency on websites and intellectual property, the ability of the Company to successfully integrate acquired businesses, dependency on key personnel, dependency on banking relations and the ability to comply with Credit Facility covenants, and other risks associated with its common stock, as well as any litigation to which the Company may be involved in from time to time; and other risk factors as discussed in the Company's annual report on Form 10-K for the year ended December 31, 2017 and in other filings made by the Company from time to time with the Securities and Exchange Commission, including its quarterly reports on Form 10-Q. Our annual report on Form 10-K is available on the SEC's EDGAR website at www.sec.gov, and a copy may also be obtained by contacting the Company. All forward-looking statements made in this press release speak only as of the date hereof. We do not intend, and do not undertake any obligation, to update any forward-looking statements to reflect future events or circumstances after the date of such statements, except as required by law.
Additional information about InfuSystem Holdings, Inc. is available at www.infusystem.com.
Joe Dorame, Joe Diaz & Robert Blum
Lytham Partners, LLC
View original content to download multimedia:http://www.prnewswire.com/news-releases/infusystem-holdings-to-feature-infublock--its-highly-effective-alternative-to-opioid-pain-management---at-outpatient-surgery-magazines-or-excellence-conference-300722497.html
SOURCE InfuSystem Holdings, Inc.
Company Codes: AMEX:INFU